Gilead (NASDAQ:GILD) just released data for a new hepatitis C combination therapy, and the results are staggering: a 100% cure rate! The news sent the stock soaring more than 13% on Monday. In this video, Motley Fool health care analyst Brenton Flynn breaks down the market potential for Gilead's new therapy and talks about another company with similarly excellent results that will want a share of that market for itself.
Free Article
You're reading a free article with opinions that may differ from The Motley Fool's Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.